Antibiotic (Carbapenem antibiotic and renal dehydropeptidase I inhibitor)

Lower respiratory tract infections, complicated and uncomplicated urinary tract infections, intra-abdominal infections, gynaecological infections, bacterial septicemia, skin and soft tissue infections, bone and joint infections, endocarditis and polymicrobic infections

Each vial contains sterile lmipenem U.S.P equivalent to Anhydrous lmipenem 500 mg and sterile cilastatin sodium U.S.P equivalent to cilastatin 500mg

1 vial/ Box

The recommended dosage is 250mg to 1 gram given intravenously every 6 to 8 hours or in intramuscular dosage of not more than 1.5g daily, usually 5 to 14 days

Individuals with known hypersensitivity to the active substance or to any of the excipients used in the formulation.

Generally well tolerated. Side effect rarely require cessation of therapy and are generally mild and transient, serious side effects are rare.

Generalized seizures have been reported in patients who received ganciclovir and imipenem-cilastatin. These drugs should not be used concomitantly unless the potential benefits outweighs the risks. Concomitant administration of imipenem-cilastain and probenecid results in only minimal increases in plasma levels and half-life of imipenem, with urinary recovery of active imipenem reduced to approximately 60% of administered dose. However, the plasma levels and half-life of cilastatin are almost doubled. Concomitant administration probenecid with imipenem-cilastatin is not recommended. Imipenem-cilastatin should not be mixed with or physically added to other antibiotics. However, imipenem-cilastatin may be administered concomitantly with other antibiotics, such as aminoglycosides.

Zeiss Pharmaceuticals Pvt. Ltd., India